The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Adverse events of special interest (AESI)
Timeframe: up to 15 years post EDIT-301 infusion
Adverse events of interest (AEI)
Timeframe: up to 15 years post EDIT-301 infusion
All-cause mortality
Timeframe: up to 15 years post EDIT-301 infusion
Adverse events (AEs) related to EDIT-301
Timeframe: up to 15 years post EDIT-301 infusion
Serious adverse events (SAEs)
Timeframe: up to 15 years post EDIT-301 infusion